Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA Jr, Horwitz SM, Kumar A, Matasar MJ, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ.

Blood. 2019 Feb 15. pii: blood-2018-10-877761. doi: 10.1182/blood-2018-10-877761. [Epub ahead of print]

PMID:
30770396
2.

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ.

Haematologica. 2019 Feb;104(2):e65-e67. doi: 10.3324/haematol.2018.199844. Epub 2018 Sep 6. No abstract available.

3.

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.

Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, Kumar A, Noy A, Palomba ML, Portlock CS, Straus DJ, Zelenetz AD, McCall SJ, Miller ST, Courtien AI, Younes A, Moskowitz CH.

Blood. 2018 Apr 19;131(16):1805-1808. doi: 10.1182/blood-2017-08-802561. Epub 2018 Jan 31.

PMID:
29386196
4.

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH.

Blood. 2017 Nov 16;130(20):2196-2203. doi: 10.1182/blood-2017-06-788877. Epub 2017 Sep 5.

5.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF.

Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.

6.

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH.

Blood. 2016 Sep 15;128(11):1458-64. doi: 10.1182/blood-2016-03-703470. Epub 2016 Jul 25.

7.

A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma.

Portlock CS, Hamlin PA, Gerecitano JF, Noy A, Palomba ML, Walkley J, Corcoran S, Migliacci J, Schoder H, Papanicolaou G, Markowitz AJ.

Tumor Microenviron Ther. 2015 Feb;2(1):14-18. Epub 2015 Feb 18.

8.
9.

Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.

Gandikota N, Hartridge-Lambert S, Migliacci JC, Yahalom J, Portlock CS, Schöder H.

Cancer. 2015 Jun 15;121(12):1985-92. doi: 10.1002/cncr.29277. Epub 2015 Mar 4.

10.

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH.

Lancet Oncol. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Epub 2015 Feb 13.

PMID:
25683846
11.

B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins.

Ng PP, Kuo CC, Wang S, Einav S, Arcaini L, Paulli M, Portlock CS, Marcotrigiano J, Tarr A, Ball J, Levy R, Levy S.

Blood. 2014 Mar 6;123(10):1512-5. doi: 10.1182/blood-2013-10-532895. Epub 2014 Jan 21.

12.

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH.

J Clin Oncol. 2013 Feb 1;31(4):456-60. doi: 10.1200/JCO.2012.45.3308. Epub 2012 Dec 17.

13.

ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.

Hartridge-Lambert SK, Schöder H, Lim RC, Maragulia JC, Portlock CS.

Cancer. 2013 Mar 15;119(6):1203-9. doi: 10.1002/cncr.27873. Epub 2012 Nov 6.

14.

Hepatitis C and non-Hodgkin lymphoma: the clinical perspective.

Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS.

Hepatology. 2012 Feb;55(2):634-41. doi: 10.1002/hep.25499. Review.

PMID:
22120959
15.

Long-term cardiac and pulmonary complications of cancer therapy.

Yahalom J, Portlock CS.

Heart Fail Clin. 2011 Jul;7(3):403-11. doi: 10.1016/j.hfc.2011.04.002. Epub 2011 May 20.

PMID:
21749892
16.

Humidified high-flow nasal oxygen utilization in patients with cancer at Memorial Sloan-Kettering Cancer Center.

Epstein AS, Hartridge-Lambert SK, Ramaker JS, Voigt LP, Portlock CS.

J Palliat Med. 2011 Jul;14(7):835-9. doi: 10.1089/jpm.2011.0005. Epub 2011 May 20.

17.

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD.

J Clin Oncol. 2010 Apr 10;28(11):1896-903. doi: 10.1200/JCO.2009.26.5942. Epub 2010 Mar 8.

18.

Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.

Schaffel R, Hedvat CV, Teruya-Feldstein J, Persky D, Maragulia J, Lin D, Portlock CS, Moskowitz CH, Zelenetz AD.

Ann Oncol. 2010 Jan;21(1):133-9. doi: 10.1093/annonc/mdp495.

19.

Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation.

Small TN, Zelenetz AD, Noy A, Rice RD, Trippett TM, Abrey L, Portlock CS, McCullagh EJ, Vanak JM, Mulligan AM, Moskowitz CH.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1538-42. doi: 10.1016/j.bbmt.2009.07.018. Epub 2009 Sep 25.

20.

Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.

Edwards-Bennett SM, Jacks LM, Moskowitz CH, Wu EJ, Zhang Z, Noy A, Portlock CS, Straus DJ, Zelenetz AD, Yahalom J.

Ann Oncol. 2010 Mar;21(3):574-81. doi: 10.1093/annonc/mdp337. Epub 2009 Sep 16.

PMID:
19759185
21.

Long-term cardiac and pulmonary complications of cancer therapy.

Yahalom J, Portlock CS.

Hematol Oncol Clin North Am. 2008 Apr;22(2):305-18, vii. doi: 10.1016/j.hoc.2008.01.010. Review.

PMID:
18395152
22.

Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.

Portlock CS, Hamlin P, Noy A, Chey W, Gaydos CA, Palomba L, Schwartz I, Corcoran S, Rosenzweig L, Walker D, Papanicolaou G, Markowitz A.

Ann Oncol. 2008 Feb;19(2):254-8. Epub 2007 Oct 26.

PMID:
17965114
23.

Autologous transplantation using high-dose radioimmunotherapy conditioning in patients 60 years and older.

Portlock CS.

Curr Oncol Rep. 2007 Sep;9(5):372; discussion 372. No abstract available.

PMID:
17915377
24.

Enzastaurin, a targeted PKCBeta inhibitor, in relapsed or refractory DLBCL: a promising new strategy based on gene expression signature.

Portlock CS.

Curr Oncol Rep. 2007 Sep;9(5):371; discussion 371. No abstract available.

PMID:
17915376
25.

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

Moskowitz CH, Hamlin PA, Gabrilove J, Bertino JR, Portlock CS, Straus DJ, Gencarelli AN, Nimer SD, Zelenetz AD.

Ann Oncol. 2007 Nov;18(11):1842-50. Epub 2007 Sep 14.

PMID:
17872903
26.

Clinical Trials Report.

Portlock CS.

Curr Oncol Rep. 2006 Sep;8(5):355-357. No abstract available.

PMID:
16954017
27.

Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?

Portlock CS, O'Connor OA, Straus DJ, Rosenzweig L, Dumitrescu O, Lin O, Maslak P.

Leuk Lymphoma. 2006 Jul;47(7):1260-4.

PMID:
16923555
29.

Nodular lymphocyte predominant Hodgkin's disease.

Portlock CS.

Cancer Treat Res. 2006;131:353-62. Review. No abstract available.

PMID:
16704176
30.

Variable problems in lymphomas: CASE 2. Sarcoidosis mimicking progressive lymphoma.

Hollister D Jr, Lee MS, Eisen RN, Fey C, Portlock CS.

J Clin Oncol. 2005 Nov 1;23(31):8113-6. No abstract available.

PMID:
16258110
31.

Review.

Portlock CS.

Clin Adv Hematol Oncol. 2004 Dec;2(12):820. No abstract available.

PMID:
16166959
32.

Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.

Hamlin PA, Portlock CS, Straus DJ, Noy A, Singer A, Horwitz SM, Oconnor OA, Yahalom J, Zelenetz AD, Moskowitz CH.

Br J Haematol. 2005 Sep;130(5):691-9.

PMID:
16115124
33.

Should radioimmunotherapy be an initial treatment option in advanced-stage follicular lymphoma?

Portlock CS.

Nat Clin Pract Oncol. 2005 Jul;2(7):346-7. No abstract available.

PMID:
16075793
34.

Surgery does not improve survival outcomes in people with primary gastric lymphoma.

Portlock CS.

Cancer Treat Rev. 2005 Feb;31(1):49-52. No abstract available.

PMID:
15707704
35.

The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.

Portlock CS, Qin J, Schaindlin P, Roistacher N, Myers J, Filippa D, Louie D, Zelenetz AD, O'Brien JP, Moskowitz C, Norton L, Yahalom J, Straus DJ, Bertino JR.

Ann Oncol. 2004 Oct;15(10):1495-503.

PMID:
15367410
36.
37.

Variations on the CHOP regimen: I. Prospective study in the elderly with aggressive non-Hodgkin's lymphomas.

Portlock CS.

Curr Oncol Rep. 2004 Sep;6(5):357. No abstract available.

PMID:
15291977
38.

Variations on the CHOP regimen: II. Prospective study in young patients.

Portlock CS.

Curr Oncol Rep. 2004 Sep;6(5):357-8. No abstract available.

PMID:
15291976
39.

The diminishing role of surgery in the treatment of gastric lymphoma.

Yoon SS, Coit DG, Portlock CS, Karpeh MS.

Ann Surg. 2004 Jul;240(1):28-37. Review.

40.

Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease.

Portlock CS, Donnelly GB, Qin J, Straus D, Yahalom J, Zelenetz A, Noy A, O'Connor O, Horwitz S, Moskowitz C, Filippa DA.

Br J Haematol. 2004 Jun;125(6):701-8.

PMID:
15180859
41.

Unusual abdominal tumors, case 2. Localized amyloid associated with gastric adenocarcinoma.

Chang DZ, Zhang JX, Filippa DA, Portlock CS.

J Clin Oncol. 2004 Apr 15;22(8):1520-2. No abstract available.

PMID:
15084626
42.

Nemaline myopathy: a possible late complication of Hodgkin's disease therapy.

Portlock CS, Boland P, Hays AP, Antonescu CR, Rosenblum MK.

Hum Pathol. 2003 Aug;34(8):816-8.

PMID:
14506646
43.

Rituximab for Lymphocyte-predominant Hodgkin's disease.

Portlock CS.

Curr Oncol Rep. 2003 Sep;5(5):358. No abstract available.

PMID:
12895384
44.

Rituximab and CHOP for elderly patients with diffuse large B-cell lymphoma.

Portlock CS.

Curr Oncol Rep. 2003 Sep;5(5):357. No abstract available.

PMID:
12895383
45.

CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.

Pan D, Qin J, Farber C, O'Brien J, Filippa D, Portlock CS.

Leuk Lymphoma. 2003 Jun;44(6):967-71.

PMID:
12854895
46.

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.

Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, Noy A, Portlock CS, Straus DJ, Yahalom J, Nimer SD, Moskowitz CH.

Blood. 2003 Sep 15;102(6):1989-96. Epub 2003 Apr 3.

47.

Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.

Pan D, Moskowitz CH, Zelenetz AD, Straus D, Kewalaramani T, Noy A, Qin J, Teruya-Feldstein J, Portlock CS.

Cancer J. 2002 Sep-Oct;8(5):371-6.

PMID:
12416894
48.

T-cell rich B-cell lymphoma: clinical distinctiveness and response to treatment in 45 patients.

Ripp JA, Loiue DC, Chan W, Nawaz H, Portlock CS.

Leuk Lymphoma. 2002 Aug;43(8):1573-80.

PMID:
12400599
49.

Dose density and dose intensity: where does CHOP go from here?

Portlock CS.

Ann Oncol. 2002 Sep;13(9):1329-30. No abstract available.

PMID:
12196356
50.

CHOP and rituximab in elderly patients.

Portlock CS.

Curr Oncol Rep. 2002 Sep;4(5):414. No abstract available.

PMID:
12162916

Supplemental Content

Loading ...
Support Center